Shikonin suppresses ERK 1/2 phosphorylation during the early stages of adipocyte differentiation in 3T3-L1 cells by unknown
Gwon et al. BMC Complementary and Alternative Medicine 2013, 13:207
http://www.biomedcentral.com/1472-6882/13/207RESEARCH ARTICLE Open AccessShikonin suppresses ERK 1/2 phosphorylation
during the early stages of adipocyte
differentiation in 3T3-L1 cells
So Young Gwon1,2, Ji Yun Ahn1, Chang Hwa Jung1, Bo Kyung Moon2 and Tae Youl Ha1*Abstract
Background: The naphthoquinone pigment, shikonin, is a major component of Lithospermum erythrorhizon and
has been shown to have various biological functions, including antimicrobial, anti-inflammatory, and antitumor
effects. In this study, we investigated the effect of shikonin on adipocyte differentiation and its mechanism of
action in 3T3-L1 cells.
Methods: To investigate the effects of shikonin on adipocyte differentiation, 3T3-L1 cells were induced to
differentiate using 3-isobutyl-1-methylzanthine, dexamethasone, and insulin (MDI) for 8 days in the presence of 0–2
μM shikonin. Oil Red O staining was performed to determine the lipid accumulation in 3T3-L1 cells. To elucidate
the anti-adipogenic mechanism of shikonin, adipogenic transcription factors, the phosphorylation levels of ERK, and
adipogenic gene expression were analyzed by Western blotting and quantitative real-time PCR. To further confirm
that shikonin inhibits adipogenic differentiation through downregulation of ERK 1/2 activity, 3T3-L1 cells were
treated with shikonin in the presence of FGF-2, an activator, or PD98059, an inhibitor, of the ERK1/2 signaling
pathway.
Results: Shikonin effectively suppressed adipogenesis and downregulated the protein levels of 2 major
transcription factors, PPARγ and C/EBPα, as well as the adipocyte specific gene aP2 in a dose-dependent manner.
qRT-PCR analysis revealed that shikonin inhibited mRNA expression of adipogenesis-related genes, such as PPARγ,
C/EBPα, and aP2. Adipocyte differentiation was mediated by ERK 1/2 phosphorylation, which was confirmed by
pretreatment with PD98059 (an ERK 1/2 inhibitor) or FGF-2 (an ERK 1/2 activator). The phosphorylation of ERK1/2
during the early stages of adipogenesis in 3T3-L1 cells was inhibited by shikonin. We also confirmed that FGF-2-
stimulated ERK 1/2 activity was attenuated by shikonin.
Conclusions: These results demonstrate that shikonin inhibits adipogenic differentiation via suppression of the ERK
signaling pathway during the early stages of adipogenesis.
Keywords: Shikonin, ERK 1/2, 3T3-L1 adipocyte, Adipogenesis, Anti-obesityBackground
Obesity can be defined as increased fat mass due to in-
creases in the number and size of adipocytes [1]. Adi-
pose tissue plays an important role in lipid metabolism,
including the storage of triglycerides and fatty acid re-
lease. Adipocytes secrete numerous adipokines, includ-
ing leptin, adiponectin, and resistin. Therefore, white* Correspondence: tyhap@kfri.re.kr
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reproduction in any medium, provided the oradipose tissue is crucial for the maintenance of energy
homeostasis and highly influences obesity.
Adipogenesis involves undifferentiated preadipocytes
converting to differentiated adipocytes and plays a key
role in fat mass growth [2,3]. Controlling adipogenesis is
a potential strategy for obesity prevention [4]. Many
studies have demonstrated that natural compounds, such
as quercertin, genistein, and esculetin, inhibit adipo-
genesis [5-7]. Adipogenesis is regulated by a number of
transcription factors, such as CCAAT/enhancer binding
proteins (C/EBPs) and peroxisome proliferator-activatedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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duces the expression of PPARγ and C/EBPα. PPARγ and
C/EBPα activate the expression of a number of genes in-
duced during adipocyte differentiation, including genes
responsible for lipid accumulation and insulin sensitivity
[8]. The mitogen-activated protein kinase (MAPK) path-
way regulates the expression of adipogenic transcription
factors during the adipogenesis [9]. MAPKs comprise
three groups: extracellular signal-regulated kinases 1 and
2 (ERK1/2), c-Jun amino-terminal kinases (JNKs), and
p38. The extracellular signal-regulated kinases 1 and 2
(ERK1/2) regulate cell proliferation and are necessary for
initiating the differentiation process in pre-adipocyte
[10]. For example, ERK phosphorylation was increased
during the early stages of adipocyte differentiation in
embryonic stem cells [11].
Shikonin, the major compound in Lithospermum
erythrorhizon (LE), has many beneficial effects on wound
healing, including anti-inflammatory and anti-tumor ef-
fects [12-14]. Recent studies have shown that shikonin
derivatives inhibit adipogenesis [15,16]. Our previous
study demonstrated the active compounds of L. erythror-
hizon; acetylshikonin has been shown to exert anti-
obesity effects in vivo [17]. Yoon et al. also demonstrated
the anti-adipogenic functions of shikonin in adipocyte
differentiation [15,16]. Based on these reports, we ex-
plored the antiobesity effect of shikonin as a potential
ERK inhibitor. In addition, the effects of shikonin on
3T3-L1 cells at early differentiation stages have not been
reported. Therefore, this study sought to characterize the
effects of shikonin, focusing on ERK phosphorylation dur-
ing the early stages of adipogenesis in 3T3-L1 cells, and
explored possible underlying molecular mechanisms.
Methods
Cell culture and differentiation
3T3-L1 mouse fibroblast cells (American Type Culture Col-
lection Manassas, VA, USA) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% calf
serum, 100 U/ml penicillin, 100 μg/ml streptomycin,
and 2 mM L-glutamine (Invitrogen, Carlsbad, CA,
USA) at 37°C under 5% CO2. On day 3 after conflu-
ence (day 0), the cells were exposed to differentiation
medium (DMEM containing 0.25 mM 3-isobutyl-1-
methylzanthine, 0.25 μM dexamethasone, and 1 μg/
mL insulin [MDI] with 10% FBS) for 2 days. The cells
were cultured for another 2 days in DMEM containing
1 μg/mL insulin and 10% FBS. The cells were then
maintained in postdifferentiation medium (DMEM
containing 10% FBS), and the medium was replaced
every 2 days. To evaluate the effects of shikonin on
preadipocyte differentiation, the cells were cultured
with differentiation medium in the presence of various
concentrations (0.5-2 μM) of shikonin. Shikonin waspurchased from Calbiochem (San Diego, CA, USA). A
range of concentrations of shikonin was prepared by
serial dilution of a stock solution with DMSO. The
cells were harvested on day 8, when differentiation
was complete. For early-stage adipogenesis analysis,
the cells were treated with PD98059 or FGF-2 and
harvested hourly.
MTT assay
Cell viability was determined by an MTT assay in 96-
well plates. Pre-adipocytes were seeded at a density of
5 × 103 cells per well. After 24 h incubation, cells were
treated with different concentrations (0.5 - 10 μM) of
shikonin for 48 h. After 48 h in culture, the cells were
then treated with 5 mg/ml MTT at 37°C for 4 h. The re-
duction product, MTT-formazan, was solubilized with
Dimethyl sulfoxide (DMSO). Absorption at 490 nm of
each sample solution was considered to represent the
MTT-reducing activity of the cells.
Oil Red O staining and cell quantification
After differentiation was induced, cells were stained with
Oil Red O (0.2% Oil Red O in 60% isopropanol). Oil Red
O staining was determined using a modified protocol
described by Ramírez-Zacarías JL et al. [18]. The cells
were washed twice with phosphate buffered saline (PBS),
fixed with 10% formalin for 1 h, dried, and stained with
Oil Red O for 10 min. The cells were washed with 70%
ethanol and water and then dried. The lipid content of
stained cells was visualized by microscopy (Olympus
IX71, Tokyo, Japan). The stained lipid droplets were
dissolved in isopropanol and quantified by measuring
absorbance at 510 nm.
Protein extraction and western blot analysis
For the Western blot analysis, cells were washed with
ice-cold PBS, collected, and centrifuged. The harvested
cells were sonicated for 5 seconds at 40 W. Cell lysates
were incubated for 20 to 30 min on ice and then
centrifuged at 13,000 rpm at 4°C for 10 min. The protein
concentration of the supernatant was determined with
the Bio-Rad Protein Assay Reagent (Bio-Rad Laborator-
ies, Hercules, CA, USA) using bovine serum albumin as
the standard. Total proteins (30 μg per lane) were se-
parated by 10% SDS-polyacrylamide gel electrophoresis
and transferred to polyvinylidenedifluoride (PVDF) mem-
branes (Millipore, Billerica, MA, USA). The membranes
were blocked for 2 h at room temperature with 0.1% Tween
20 (Amresco Inc., Solon, OH, USA) in Tris-buffered saline
containing 5% skim milk. After overnight incubation at 4°C
with primary antibodies, the membranes were incubated
with a horseradish peroxidase-conjugated secondary anti-
body for 1 h at room temperature. Immunodetection was
carried out with ECL detection reagent (Amersham
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sults of quantitative analysis include data from at least
three independent experiments.
RNA extraction and real-time quantitative RT-PCR
Total RNA was isolated from 3T3-L1 adipocytes using the
RNase kit (Nucleospin, iNtRON Biotechnology) and used
to synthesize cDNA for analysis by real-time reverse
transcription-polymerase chain reaction (RT-PCR) (Light
CyclerW 480 System, Roche, Basel, Swiss). Quantitative
real-time PCR was performed in a 20 μl reaction mixture.
The cycle conditions were as follows: 95°C for 5 min,
followed by 50 cycles involving denaturing at 95°C for 20
s, annealing at 55°C for 15 s, and extension at 72°C for 30 s.
The primer sequences were as follows: PPARγ forward 5′-
TCGCTGATGCACTGCCTATG-3′; PPARγ reverse 5′-G
AGAGGTCCACAGAGCTGATT-3′; C/EBPα forward 5′-
GACTTCAGCCCC TACCTGGA-3′; C/EBPα reverse 5′-
GTAGTCGTCGGCGAAGAGGT-3′; aP2 forward 5′-AGG
CTC ATAGCACCCTCCTGTG-3′; aP2 reverse 5′-CAG
GTTCCCACAAAGGCATCAC-3′; LPL forward 5′-TGTA
ACAATCTGGGCTATGAGATCAAC-3′; LPL reverse 5′-
TCTTGCCATCCTCAGTC CC-3′; ERK forward 5′-GCT
CACCCTTACCTGGAACA-3′; and ERK reverse 5′-GGA
CCAGAT CCAAAAGGACA-3′.Figure 1 Effect of shikonin on the lipid accumulation of 3T3-L1 adipo
content was assessed by Oil Red O staining. (C) The absorbance of Oil Red
at 500 nm.Statistical analysis
Group results were compared by an analysis of variance
(ANOVA), followed by Duncan’s test using SPSS 18.0 soft-
ware. Data are expressed as the mean ± standard error of
the mean (SEM). P < 0.05 was considered significant.
Results
Shikonin inhibits differentiation of 3T3-L1 preadipocytes
We performed an MTT assay to analyze the viability of
3T3-L1 preadipocyte cells treated with shikonin for 48
h. Shikonin did not show any effects on cell viability and
cytotoxicity (Figure 1C).
To investigate the effects of shikonin on adipocyte
differentiation, 3T3-L1 cells were induced to dif-
ferentiate with MDI in the presence or absence of
shikonin for 8 days. The effect of shikonin on the lipid
accumulation of adipocytes was measured by Oil Red
O staining. Shikonin inhibited the differentiation
of 3T3-L1 pre-adipocytes in a dose-dependent manner
(Figure 1A-B). Treatment with 0.5, 1 and 2 μM shi-
konin significantly decreased lipid droplets by 25.2%,
67.2% (P < 0.05), and 76.4% (P < 0.01), respectively,
compared with MDI-treated cells. These results dem-
onstrated that shikonin inhibited the differentiation of
pre-adipocytes.cytes. (A) Cell viability was determined by an MTT assay. (B) The lipid
O dissolved in isoprophanol was spectrophotometrically determined
Figure 2 Effect of shikonin on adipogenic transcription factor protein levels and gene expression in 3T3-L1 adipocytes. (A) Western blot
analysis was performed with antibodies against PPARγ, C/EBPα, aP2, and β-actin. (B) The expression of PPARγ, C/EBPα, and aP2mRNAs from
3T3-L1 adipocytes was measured by qRT-PCR.
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transcription factors and genes
Next, to examine whether shikonin inhibits adipocyte dif-
ferentiation through the downregulation of adipogenic
transcription factors and their target genes, we performed
Western blotting and quantitative real-time PCR to
analyze the protein and mRNA expression of PPARg, C/
EBPa, and aP2. The protein levels of PPARγ, C/EBPα, and
aP2 decreased with increasing dosages of shikonin in 3T3-
L1 cells (Figure 2). Consistently, the mRNA expression of
PPARγ, C/EBPα, and aP2 was also reduced by shikonin
(Figure 2). These results demonstrate that shikonin in-
hibits adipogenesis through the downregulation of adi-
pogenic transcription factors and their genes.Figure 3 Inhibitory effect of shikonin on ERK 1/2 phosphorylation in
determined with ERK 1/2. (C) Time-course of ERK expression as measured bShikonin inhibits adipogenesis through the suppression
of ERK 1/2 phosphorylation
Many studies have suggested that MAPKs promote
early-stage adipocyte differentiation by activating tran-
scription factors [11,19-21]. The ERK1/2 signaling path-
ways has been reported to play a critical role for
controlling adipogenesis [22]. To elucidate possible
mechanisms underlying the inhibition of adipocyte dif-
ferentiation by shikonin, we further examined whether
regulation of ERK 1/2 phosphorylation is associated with
the inhibition of adipocyte differentiation by shikonin
(Figure 3A). Interestingly, shikonin markedly decreased
the phosphorylation of ERK 1/2 in a dose-dependent
manner. Additionally, mRNA expression of ERK 1/2 was3T3-L1 adipocytes. (A) Protein level and (B) mRNA expression were
y qRT-PCR.
Figure 4 Effects of the ERK inhibitor and activator on the inhibition of adipocyte differentiation by shikonin. (A) The protein level and
mRNA expression were determined with ERK 1/2. Cells were treated with (A) Shikonin (1 μM) and the ERK inhibitor PD98059 (10 μM) during
adipocyte differentiation. After 8 days, the cells were stained with Oil Red O to determine the degree of lipid accumulation. The inhibitory effects
of shikonin and PD98059 on ERK 1/2 signaling pathway were observed during adipocyte differentiation. (B) Western blot analysis performed with
the ERK pathway and adipogenic marker genes.
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effect of shikonin on ERK 1/2 mRNA expression at vari-
ous time points during adipocyte differentiation. MDI-
treated control cell showed significantly elevated ERK 1/2
phosphorylation between day 0 and day 2 compared with
shikonin-treated cells. However, shikonin significantly
downregulated ERK mRNA levels from day 4 to 6. These
results suggest that shikonin inhibited adipocyte differenti-
ation in the early stages.
Next, we sought to determine whether shikonin inhibits
adipocyte differentiation via ERK 1/2 signaling pathway.
3T3-L1 cells were pretreated with ERK inhibitor PD98059
[23] or ERK activator FGF-2 [24] for 30 min, followed
by induction of differentiation by MDI with or without
shikonin (Figure 3B). Mature lipid accumulation and
adipogenesis-related markers in matured adipocytes were
determined on day 8 after treatment with MDI. As shown
Figure 3B, pretreatment with PD98059 attenuated adipo-
cyte differentiation. Shikonin also inhibited differentiation;
the resulting adipocyte differentiationlevels were similar to
those obtained with PD98059. Pretreatment with ERK
activator FGF-2 increased the lipid droplet similar to
MDI-treated control cells. However, shikonin decreased
FGF-2–mediated activation of ERK 1/2 in 3T3-L1 cells.
PD98059 and shikonin consistently reduced the pro-
tein levels of adipogenic transcription factors (Figure 3C).
In contrast, FGF-2 increased the protein levels of PPARγ,
C/EBPα, and aP2. Additionally, co-treatment with shi-
konin and FGF-2 decreased the levels of these tran-
scription factors compared with FGF-2-treated cells. Increased phosphorylation of ERK 1/2 was observed after
FGF-2 stimulation in 3T3-L1 cells, whereas the phos-
phorylation levels were reduced by shikonin. Moreover,
the inhibition of adipocyte differentiation was in accord-
ance with the decrease in ERK1/2 phosphorylation; thus,
inhibition of adipocyte differentiation by shikonin may
be due to suppression of ERK 1/2 signaling. These re-
sults suggest that shikonin plays an important role in
the inhibition of adipocyte differentiation via suppres-
sion of ERK 1/2 phosphorylation.
Shikonin regulates ERK 1/2 phosphorylation in the early
stages of adipogenesis
ERK has been reported to promote differentiation in the
early stages of adipogenesis in 3T3-L1 cells [9,25]. To
confirm whether shikonin inhibits ERK phosphorylation
in the early stages of adipogenesis, we examined time-
course response of ERK 1/2 phosphorylation during the
early differentiation period. Cells were pretreated with
PD98059 (10 μM) or FGF-2 (1 nM) for 30 min prior to
incubation with MDI in the presence or absence of 1
μM shikonin. ERK phosphorylation was determined at 5,
15, 30 min and 1 h after MDI treatment by Western
blotting. As shown in Figure 4A, phosphorylation of
ERK 1/2 was rapidly induced at 5 min after MDI treat-
ment and maintained. FGF-2 also showed effects similar
to MDI. ERK 1/2 phosphorylation was observed at 15 min
after pretreatment of PD98059 and ceased after 1 h.
ERK 1/2 phosphorylation was completely inhibited
30 min after treatment with shikonin. These results
Figure 5 Effect of shikonin on the ERK pathway during the early stages of adipogenesis. (A) The time-dependent effect of PD98059
(10 μM), FGF-2 (1 nM), and shikonin (1 μM) on ERK 1/2 activity was analyzed by Western blotting. (B) The cells were treated with shikonin (2 μM)
plus different doses of FGF-2. Cells were harvested at 10 min and examined with Western blotting as described in the Figure 2 legend.
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adipogenesis after MDI treatment. To confirm the re-
covery effect of FGF-2 on ERK 1/2 phosphorylation
inhibited by shikonin, cells were pretreated with 2 μM
shikonin for 10 min and then various concentrations of
FGF-2 for 30 min. As shown in Figure 4B, shikonin-
mediated inhibition of ERK 1/2 phosphorylation was in-
creased in a dose-dependent manner by FGF-2. These
results showed that shikonin has an acute, direct effect
on the ERK 1/2 signaling pathway through inhibition of
ERK 1/2 phosphorylation.
Discussion
Increased consumption of calorie-enriched foods with
sugar and fats and a lack of physical activity lead to
obesity. Obesity is a major risk for serious chronic
diseases, including diabetes, cardiovascular disease,
hypertension, and other health problems [1]. Adipocyte
differentiation is an adaptive response to excess energy
intake and induces obesity and metabolic diseases [8].
Accordingly, adipocytes are a therapeutic target for
obesity, and many studies are being undertaken to
prevent obesity through regulating adipogenesis. Many
plants and phytochemicals have been reported to have
biological activities without any side effects. Shikonin
derivatives are a major compound of Lithospermum
erythrorhizon, and shikonin has been reported to have
antimicrobial, anti-inflammatory, and antitumor effects
[12-14]. Shikonin and its derivatives, such as acetyl-
shikonin and isobytyrylshikonin, have a similar struc-
ture and therefore have similar biological activity that
acts through multiple mechanisms [13,26-29]. Here,
we investigated the effect of shikonin on 3T3-L1 pre-
adipocyte differentiation, focusing on the suppression
of ERK 1/2 phosphorylation at the early stages of
adipogenesis.
In the present study, shikonin significantly suppressed
adipogenesis, which is characterized by increased lipid
droplets in 3T3-L1 cells, and decreased the levels ofadipogenic transcription factors, including PPARγ, C/
EBPα, and the adipocyte-specific gene aP2.
Previous reports have shown that the MEK inhibitor,
PD98059, significantly attenuates adipocyte differenti-
ation and that FGF-2 induces the activation of the ERK
1/2 signaling pathway [30]. Based on these findings, the
ERK 1/2 inhibitor, PD98059, and activator, FGF-2, were
used to determine whether the anti-adipogenesis in-
duced by shikonin is related to ERK 1/2 phosphoryl-
ation. Shikonin significantly inhibited ERK 1/2 phos
phorylation and mRNA expression; PD98059 showed
similar effects. As expected, FGF-2 treatment induced
ERK 1/2 phosphorylation. We further confirmed that
shikonin suppressed ERK 1/2 phosphorylation in the
early stages of adipogenesis. These results are the first
demonstration of the inhibition of ERK 1/2 signaling by
shikonin.
The transcription factors PPARγ and C/EBPα have
been demonstrated to play key roles in adipogenesis
[2,3]. PPARγ, a member of the nuclear-receptor super-
family, is a master regulator of adipogenesis [31]. C/
EBPα is required to maintain PPARγ expression and reg-
ulates insulin sensitivity in adipocytes [32]. Our results
indicated that shikonin significantly suppressed lipid ac-
cumulation in dose-dependent manner via the decreased
expression of PPARγ, C/EBPα, and aP2 (Figures 1, 2),
which is consistent with the results of Yoon et al. [15].
aP2 is a member of the cytoplasmic fatty acid binding
protein family, and its expression is highly regulated dur-
ing the differentiation of adipocytes [33]. It is generally
recognized that PPARγ and C/EBPα activate the down-
stream terminal adipocyte differentiation marker genes of
aP2 [34].
Adipocyte differentiation involves complex cellular path-
ways and requires the sequential regulation of adipogenic
and lipogenic genes [19]. The MAPK signaling pathways
activate a variety of transcription factors involved in adipo-
cyte growth and differentiation [35]. Previous studies have
suggested that p38 has positive and negative effects on
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been reported to play an essential role in cell proliferation
and controlling adipogenesis [21]. ERK phosphorylation is
necessary for the expression of the adipogenic transcrip-
tional factors PPARγ and C/EBPα [24,38]. The present
study showed that ERK 1/2 phosphorylation was sup-
pressed by shikonin. Additionally, shikonin markedly re-
duced ERK 1/2 mRNA expression (Figure 3).
To confirm the more specific role of shikonin in the
ERK signaling pathway, cells were treated with PD98059
or FGF-2. Pretreatment with PD98059 blocked ERK 1/2
phosphorylation and inhibited adipocyte differentiation
(Figure 4). Similarly, shikonin also inhibited the phos-
phorylation of ERK 1/2, as well as the protein levels of
adipogenic transcription factors. Furthermore, pretreat-
ment with FGF-2 stimulated ERK 1/2 phosphorylation,
and shikonin markedly attenuated the FGF-2-induced
phosphorylation of ERK 1/2 (Figure 4B).
Shikonin treatment inhibited ERK 1/2 phosphory-
lation in a time-dependent manner, which suggests that
shikonin inhibits adipocyte differentiation by regulating
ERK 1/2 phosphorylation in the early stages of adipogenesis
(Figure 5A). To further confirm the inhibition of ERK 1/2
phosphorylation by shikonin, we investigated whether
shikonin has a direct effect on ERK 1/2 phosphoryl-
ation. As expected, FGF-2 treatment inhibited shikonin-
induced ERK 1/2 phosphorylation (Figure 5B). Taken
together, these findings suggest that shikonin is able to
block ERK phosphorylation at an early stage and inhibit
the expression of adipogenic transcription factors by
modulating the ERK-mediated signaling pathway during
adipocyte differentiation. Further in vivo studies are ne-
cessary to determine the molecular mechanisms of
shikonin-induced ERK 1/2 phosphorylation inhibition.Conclusions
Our results show that shikonin suppresses adipogenesis in
3T3-L1 cells by downregulating the expression of PPARγ
and C/EBPα through the ERK signalling pathway at the
early stages of adipogenesis. Therefore, these data indicate
that shikonin is a potent and specific inhibitor of the ERK
pathway in adipocyte differentiation and that shikonin
may be useful agent in the prevention of obesity. Further
studies are needed to elucidate the potential role of kinase
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